产品种类

  THERAPEUTIC AREA PRODUCT STATUS PARTNER
MARKETED PORTFOLIO

“…it's not enough anymore just to have generics. That might work for the immediate future…but beyond that you need to have differentiated products if you want to remain or become a player in the pharmaceutical market.”

-Dr. Blobel on evolving China pharma market,
  BioWorld Today, November 13, 2013

HBV, HCV, Cancer, Vaccine Adjuvant; Sepsis ZADAXIN Marketed since 1996 SciClone Proprietary

Oncology

Holoxan

Mesna

Endoxan

Methotrexate

Farlutal

Estracyt

DC Bead

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Baxter

Baxter

Baxter

Pfizer

Pfizer

Pfizer

BTG

赛生公司正运用现有技术打造一系列高质量且与众不同的品牌产品,在肿瘤、心血管疾病和传染性疾病等主要治疗领域为中国患者人群提供安全有效的治疗。每一款产品均通过实例证明其适合中国医药市场的发展。

我们销售的产品组合主要包括我们的专有旗舰产品、免疫调节剂日达仙、新推出的新型肿瘤产品DC Bead®以及一系列标准肿瘤治疗产品。

  THERAPEUTIC AREA PRODUCT STATUS PARTNER
DEVELOPMENT PORTFOLIO

Oncology

 

SGX942

ABTL0812

PT-112

Phase 2

Early Clinical

Phase 1

Soligenix, Inc.

Ability Pharma

Phosplatin Therapeutics

Cardiovascular

Angiomax

Neucardin

Cleviprex

NDA in review

Phase 3

CTA application filed

The Medicines Co.

Zensun

The Medicines Co.

Anti-Infective

Loramyc

VIBATIV

NDA in preparation

CTA application planning

Onxeo

Theravance Biopharma

我们的开发组合包括已获得西方市场许可并有潜力成为治疗类药物领导者的药品,如心血管药物比伐卢定和 Neucardin™ 以及抗生素 ,这些药物均可以通过监管流程并获取中期市场机会。

我们与领先的制药和生物技术公司进行了有针对性的成功合作。这些公司包括位于美国、欧洲、中国和台湾各地区的跨国企业和创新型生物制药公司。通过此合作,我们构建出了这一有吸引力的开发组合。

© 2017 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer. Terms of Use | Notes Regarding Forward Looking Statements